FIghtMND invites letters of intent for its clinical trial grants. These support novel, high-potential treatments for motor neurone diseases, including amyotrophic lateral sclerosis, within the Australian clinical trials consortium of hospitals.
The call is intended for academic-industry partnerships.
Funding & Duration
Grants are worth between $500,000 and $1M each for a phase II trial, and up to $1.5M each for a phase III trial.
Projects may have a duration of two years.
Applications are open to researchers worldwide. An Australian site to trial is mandatory.
Submission Requirements & Due Date
- 11 January 2019 – Letter of Intent Submitted to email@example.com
- 25 March 2019 – Invited applications must be submitted for internal review
- Please email firstname.lastname@example.org if you are considering applying for this scheme.
- See also: Submitting an Application to Research Services for Review